Company Description
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide.
Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.
The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.
iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jun 17, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Tracy Curley |
Contact Details
Address: 450 Bedford Street Lexington, Massachusetts 02420 United States | |
| Phone | 781 301 6700 |
| Website | ispecimen.com |
Stock Details
| Ticker Symbol | ISPC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001558569 |
| CUSIP Number | 45032V108 |
| ISIN Number | US45032V1089 |
| Employer ID | 27-0480143 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Tracy Wilson Curley | Chief Executive Officer, Chief Financial Officer, Treasurer and Director |
| Leslie Hoyt | Senior Vice President of Operations |
| Carly Lejnieks | Vice President of Marketing |
| Annette Arnold | Vice President of Sales and Business Development |
| Evan Cox | Senior Vice President of Strategy and Innovation |
| Brielan Smiechowski | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 424B4 | Prospectus |
| Oct 29, 2024 | EFFECT | Notice of Effectiveness |
| Oct 18, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 2, 2024 | 8-K | Current Report |
| Sep 25, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 8-K | Current Report |
| Aug 6, 2024 | 8-K | Current Report |